β-Blockers for the treatment of cardiac arrest from ventricular fibrillation?

Resuscitation

Volumn 75, Issue 3, 2007, Pages 434-444

  Bourque, Daniel ^a   Daoust, Raoul ^a,b   Huard, Vérilibe ^a,b   Charneux, Marco ^a,b  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Advanced life support (ALS); Cardiac arrest; Cardiopulmonary resuscitation (CPR); Heart arrest; Propranolol; Resuscitation; Ventricular fibrillation; Adrenergic antagonist

Indexed keywords

21 [4 [2,6 BIS(1 PYRROLIDINYL) 4 PYRIMIDINYL] 1 PIPERAZINYL]PREGNA 1,4,9(11) TRIENE 3,20 DIONE; ADRENALIN; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ESMOLOL; ISOPRENALINE; LEVOSIMENDAN; LIDOCAINE; METOPROLOL; OXEDRINE; PHENYLEPHRINE; PLACEBO; PRAZOSIN; PROPRANOLOL; SOTALOL; VASOPRESSIN;

CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; HEART ARREST; HEART FUNCTION; HEART VENTRICLE FIBRILLATION; HUMAN; LOW DRUG DOSE; MORTALITY; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RESUSCITATION; REVIEW; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 35748979399     PISSN: 03009572     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resuscitation.2007.05.013     Document Type: Review

References (88)

1. Chugh S.S., Jui J., Gunson K., et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol 44 (2004) 1268-1275
2. Cobb L.A., Fahrenbruch C.E., Olsufka M., and Copass M.K. Changing incidence of out-of-hospital ventricular fibrillation, 1980-2000. JAMA 288 (2002) 3008-3013
3. Rea T.D., Eisenberg M.S., Sinibaldi G., and White R.D. Incidence of EMS-treated out-of-hospital cardiac arrest in the United States. Resuscitation 63 (2004) 17-24
4. Herlitz J., Engdahl J., Svensson L., Young M., Angquist K.A., and Holmberg S. Decrease in the occurrence of ventricular fibrillation as the initially observed arrhythmia after out-of-hospital cardiac arrest during 11 years in Sweden. Resuscitation 60 (2004) 283-290
5. Vaillancourt C., and Stiell I.G. Cardiac arrest care and emergency medical services in Canada. Can J Cardiol 20 (2004) 1081-1090
6. Eisenberg M.S., Horwood B.T., Cummins R.O., Reynolds-Haertle R., and Hearne T.R. Cardiac arrest and resuscitation: a tale of 29 cities. Ann Emerg Med 19 (1990) 179-186
7. Bunch T.J., White R.D., Gersh B.J., et al. Long-term outcomes of out-of-hospital cardiac arrest after successful early defibrillation. N Engl J Med 348 (2003) 2626-2633
8. Valenzuela T.D., Roe D.J., Nichol G., Clark L.L., Spaite D.W., and Hardman R.G. Outcomes of rapid defibrillation by security officers after cardiac arrest in casinos. N Engl J Med 343 (2000) 1206-1209
9. Herlitz J., Bang A., Holmberg M., Axelsson A., Lindkvist J., and Holmberg S. Rhythm changes during resuscitation from ventricular fibrillation in relation to delay until defibrillation, number of shocks delivered and survival. Resuscitation 34 (1997) 17-22
10. Allegra J., Lavery R., Cody R., et al. Magnesium sulfate in the treatment of refractory ventricular fibrillation in the prehospital setting. Resuscitation 49 (2001) 245-249
11. Dorian P., Cass D., Schwartz B., Cooper R., Gelaznikas R., and Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 346 (2002) 884-890
12. Hassan T.B., Jagger C., and Barnett D.B. A randomised trial to investigate the efficacy of magnesium sulphate for refractory ventricular fibrillation. Emerg Med J 19 (2002) 57-62
13. Herlitz J., Ekstrom L., Wennerblom B., et al. Lidocaine in out-of-hospital ventricular fibrillation. Does it improve survival?. Resuscitation 33 (1997) 199-205
14. Kudenchuk P.J., Cobb L.A., Copass M.K., et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 341 (1999) 871-878
15. 2005 American Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 112 IV (2005) 1-203
16. Otto C.W., Yakaitis R.W., and Blitt C.D. Mechanism of action of epinephrine in resuscitation from asphyxial arrest. Crit Care Med 9 (1981) 321-324
17. Yakaitis R.W., Otto C.W., and Blitt C.D. Relative importance of alpha and beta adrenergic receptors during resuscitation. Crit Care Med 7 (1979) 293-296
18. Michael J.R., Guerci A.D., Koehler R.C., et al. Mechanisms by which epinephrine augments cerebral and myocardial perfusion during cardiopulmonary resuscitation in dogs. Circulation 69 (1984) 822-835
19. Kern K.B., Ewy G.A., Voorhees W.D., Babbs C.F., and Tacker W.A. Myocardial perfusion pressure: a predictor of 24-h survival during prolonged cardiac arrest in dogs. Resuscitation 16 (1988) 241-250
20. Sanders A.B., Ewy G.A., and Taft T.V. Prognostic and therapeutic importance of the aortic diastolic pressure in resuscitation from cardiac arrest. Crit Care Med 12 (1984) 871-873
21. Paradis N.A., Martin G.B., Rivers E.P., et al. Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation. JAMA 263 (1990) 1106-1113
22. Tisdale J.E., Patel R.V., Webb C.R., Borzak S., and Zarowitz B.J. Proarrhythmic effects of intravenous vasopressors. Ann Pharmacother 29 (1995) 269-281
23. Tang W., Weil M.H., Gazmuri R.J., Sun S., Duggal C., and Bisera J. Pulmonary ventilation/perfusion defects induced by epinephrine during cardiopulmonary resuscitation. Circulation 84 (1991) 2101-2107
24. Thrush D.N., Downs J.B., and Smith R.A. Is epinephrine contraindicated during cardiopulmonary resuscitation?. Circulation 96 (1997) 2709-2714
25. Rivers E.P., Wortsman J., Rady M.Y., Blake H.C., McGeorge F.T., and Buderer N.M. The effect of the total cumulative epinephrine dose administered during human CPR on hemodynamic, oxygen transport, and utilization variables in the postresuscitation period. Chest 106 (1994) 1499-1507
26. Tang W., Weil M.H., Sun S., Noc M., Yang L., and Gazmuri R.J. Epinephrine increases the severity of postresuscitation myocardial dysfunction. Circulation 92 (1995) 3089-3093
27. Ditchey R.V., and Lindenfeld J. Failure of epinephrine to improve the balance between myocardial oxygen supply and demand during closed-chest resuscitation in dogs. Circulation 78 (1988) 382-389
28. Lindner K.H., Ahnefeld F.W., Schuermann W., and Bowdler I.M. Epinephrine and norepinephrine in cardiopulmonary resuscitation. Effects on myocardial oxygen delivery and consumption. Chest 97 (1990) 1458-1462
29. Livesay J.J., Follette D.M., Fey K.H., et al. Optimizing myocardial supply/demand balance with alpha-adrenergic drugs during cardiopulmonary resuscitation. J Thorac Cardiovasc Surg 76 (1978) 244-251
30. Monroe R.G., and French G. Ventricular pressure-volume relationships and oxygen consumption in fibrillation and arrest. Circ Res 8 (1960) 260-266
31. Ditchey R.V., Goto Y., and Lindenfeld J. Myocardial oxygen requirements during experimental cardiopulmonary resuscitation. Cardiovasc Res 26 (1992) 791-797
32. Yaku H., Goto Y., Ohgoshi Y., et al. Determinants of myocardial oxygen consumption in fibrillating dog hearts. Comparison between normothermia and hypothermia. J Thorac Cardiovasc Surg 105 (1993) 679-688
33. Gazmuri R.J., and Becker J. Cardiac resuscitation. The search for hemodynamically more effective methods. Chest 111 (1997) 712-723
34. Kern K.B., Elchisak M.A., Sanders A.B., Badylak S.F., Tacker W.A., and Ewy G.A. Plasma catecholamines and resuscitation from prolonged cardiac arrest. Crit Care Med 17 (1989) 786-791
35. Lindner K.H., Haak T., Keller A., Bothner U., and Lurie K.G. Release of endogenous vasopressors during and after cardiopulmonary resuscitation. Heart 75 (1996) 145-150
36. Little R.A., Frayn K.N., Randall P.E., et al. Plasma catecholamines in patients with acute myocardial infarction and in cardiac arrest. Q J Med 54 (1985) 133-140
37. Wortsman J., Frank S., and Cryer P.E. Adrenomedullary response to maximal stress in humans. Am J Med 77 (1984) 779-784
38. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-7.
39. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247:1707-14.
40. Hjalmarson A., Elmfeldt D., Herlitz J., et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 2 (1981) 823-827
41. Teo K.K., Yusuf S., and Furberg C.D. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 270 (1993) 1589-1595
42. Yusuf S., Peto R., Lewis J., Collins R., and Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27 (1985) 335-371
43. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol 80 (1997) 35J-39J
44. Norris R.M., Barnaby P.F., Brown M.A., et al. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet 2 (1984) 883-886
45. Ryden L., Ariniego R., Arnman K., et al. A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med 308 (1983) 614-618
46. Reiter M.J., and Reiffel J.A. Importance of beta blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol 82 (1998) 9I-19I
47. Anderson J.L., Rodier H.E., and Green L.S. Comparative effects of beta-adrenergic blocking drugs on experimental ventricular fibrillation threshold. Am J Cardiol 51 (1983) 1196-1202
48. Coram W.M., Olson R.W., Beil M.E., Cabot C.F., and Weiss G.B. Effects of metoprolol, alone and in combination with lidocaine, on ventricular fibrillation threshold: comparison with atenolol, propranolol, and pindolol. J Cardiovasc Pharmacol 9 (1987) 611-621
49. Luketich J., Friehling T.D., O'Connor K.M., and Kowey P.R. The effect of beta-adrenergic blockade on vulnerability to ventricular fibrillation and inducibility of ventricular arrhythmia in short- and long-term feline infarction models. Am Heart J 118 (1989) 265-271
50. Patterson E., and Lucchesi B.R. Antifibrillatory properties of the beta-adrenergic receptor antagonists, nadolol, sotalol, atenolol and propranolol, in the anesthetized dog. Pharmacology 28 (1984) 121-129
51. Raeder E.A., Verrier R.L., and Lown B. Intrinsic sympathomimetic activity and the effects of beta-adrenergic blocking drugs on vulnerability to ventricular fibrillation. J Am Coll Cardiol 1 (1983) 1442-1446
52. Spear J.F., Moore E.N., and Ricciutti M. The effects of the d- and l-optical isomers of propranolol on the ventricular fibrillation threshold. Eur J Cardiol 7 (1978) 117-124
53. Wallis D.E., Wedel V.A., Scanlon P.J., and Euler D.E. Effect of esmolol on the ventricular fibrillation threshold. Pharmacology 36 (1988) 9-15
54. Kanter K.R., Flaherty J.T., Bulkley B.H., Gott V.L., and Gardner T.J. Beneficial effects of adding propranolol to multidose potassium cardioplegia. Circulation 64 (1981) II84-II90
55. Vejlsted H., and Andersen K. Fischer Hansen B, Husum B, Arnbjerg J. Myocardial preservation during anoxic arrest. Premedication with propranolol, verapamil or methylprednisolone. Scand J Thorac Cardiovasc Surg 17 (1983) 269-276
56. Ditchey R.V., and Slinker B.K. Phenylephrine plus propranolol improves the balance between myocardial oxygen supply and demand during experimental cardiopulmonary resuscitation. Am Heart J 127 (1994) 324-330
57. Ditchey R.V., Rubio-Perez A., and Slinker B.K. Beta-adrenergic blockade reduces myocardial injury during experimental cardiopulmonary resuscitation. J Am Coll Cardiol 24 (1994) 804-812
58. Hilwig R.W., Kern K.B., Berg R.A., Sanders A.B., Otto C.W., and Ewy G.A. Catecholamines in cardiac arrest: role of alpha agonists, beta-adrenergic blockers and high-dose epinephrine. Resuscitation 47 (2000) 203-208
59. Killingsworth C.R., Wei C.C., Dell'Italia L.J., et al. Short-acting beta-adrenergic antagonist esmolol given at reperfusion improves survival after prolonged ventricular fibrillation. Circulation 109 (2004) 2469-2474
60. Strohmenger H.U., Wenzel V., Eberhard R., Guth B.D., Lurie K.G., and Lindner K.H. Effects of the specific bradycardic agent zatebradine on hemodynamic variables and myocardial blood flow during the early postresuscitation phase in pigs. Resuscitation 42 (1999) 211-220
61. Menegazzi J.J., Seaberg D.C., Yealy D.M., Davis E.A., and MacLeod B.A. Combination pharmacotherapy with delayed countershock vs standard advanced cardiac life support after prolonged ventricular fibrillation. Prehosp Emerg Care 4 (2000) 31-37
62. Huang L., Weil M.H., Cammarata G., Sun S., and Tang W. Nonselective beta-blocking agent improves the outcome of cardiopulmonary resuscitation in a rat model. Crit Care Med 32 (2004) S378-S380
63. Pellis T., Weil M.H., Tang W., et al. Evidence favoring the use of an alpha2-selective vasopressor agent for cardiopulmonary resuscitation. Circulation 108 (2003) 2716-2721
64. Cammarata G., Weil M.H., Sun S., Tang W., Wang J., and Huang L. Beta1-adrenergic blockade during cardiopulmonary resuscitation improves survival. Crit Care Med 32 (2004) S440-S443
65. Wang J., Weil M.H., Tang W., Sun S., and Huang L. Levosimendan improves postresuscitation myocardial dysfunction after beta-adrenergic blockade. J Lab Clin Med 146 (2005) 179-183
66. Laurent I., Monchi M., Chiche J.D., et al. Reversible myocardial dysfunction in survivors of out-of-hospital cardiac arrest. J Am Coll Cardiol 40 (2002) 2110-2116
67. The Emergency Cardiac Care (ECC) Committee of the American Heart Association. Standards for cardiopulmonary resuscitation (CPR) and emergency cardiac care (ECC). 3. Advanced life support. JAMA 1974;227:Suppl:852-60.
68. Sloman G., Robinson J.S., and McLean K. Propranolol (Inderal) in Persistent Ventricular Fibrillation. Br Med J 1 (1965) 895-896
69. Ikram H. Propranolol in persistent ventricular fibrillation complicating acute myocardial infarction. Am Heart J 75 (1968) 795-798
70. Mason J.R., Marek J.C., Loeb H.S., and Scanlon P.J. Intravenous propranolol in the treatment of repetitive ventricular tachyarrhythmias during resuscitation from sudden death. Am Heart J 110 (1985) 161-165
71. Rothfeld E.L., Lipowitz M., Zucker I.R., Parsonnet V., and Bernstein A. Management of persistently recurring ventricular fibrillation with propranolol hydrochloride. JAMA 204 (1968) 546-548
72. van Dantzig J.M., Koster R.W., and Biervliet J.D. Treatment with esmolol of ventricular fibrillation unresponsive to lidocaine and procainamide. J Cardiothorac Vasc Anesth 5 (1991) 600-603
73. Schmidt T.D., and Muir A.J. A case of electrical storm in a liver transplant patient. Transplant Proc 35 (2003) 1437-1438
74. Srivatsa U.N., Ebrahimi R., El-Bialy A., and Wachsner R.Y. Electrical storm: case series and review of management. J Cardiovasc Pharmacol Ther 8 (2003) 237-246
75. Besterman E.M., and Friedlander D.H. Clinical experiences with propranolol. Postgrad Med J 41 (1965) 526-535
76. Iwatsuki K., Yusa T., Hashimoto Y., and Watabe Y. Effect of propranolol on paroxysmal ventricular fibrillation. Tohoku J Exp Med 88 (1966) 257-262
77. Tsagalou E.P., Kanakakis J., Rokas S., and Anastasiou-Nana M.I. Suppression by propranolol and amiodarone of an electrical storm refractory to metoprolol and amiodarone. Int J Cardiol 99 (2005) 341-342
78. Nademanee K., Taylor R., Bailey W.E., Rieders D.E., and Kosar E.M. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation 102 (2000) 742-747
79. Kovoor P., Love A., Hall J., et al. Randomized double-blind trial of sotalol versus lignocaine in out-of-hospital refractory cardiac arrest due to ventricular tachyarrhythmia. Intern Med J 35 (2005) 518-525
80. Bauthier J., Broekhuysen J., Charlier R., and Richard J. Nature of the inhibition by amiodarone of isoproterenol-induced tachycardia in the dog. Arch Int Pharmacodyn Ther 219 (1976) 45-51
81. Charlier R. Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors. Br J Pharmacol 39 (1970) 668-674
82. Du X.J., Esler M.D., and Dart A.M. Sympatholytic action of intravenous amiodarone in the rat heart. Circulation 91 (1995) 462-470
83. Anderson J.L., and Prystowsky E.N. Sotalol: An important new antiarrhythmic. Am Heart J 137 (1999) 388-409
84. Waldo A.L., Camm A.J., deRuyter H., et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 348 (1996) 7-12
85. Nattel S., Feder-Elituv R., Matthews C., Nayebpour M., and Talajic M. Concentration dependence of class III and beta-adrenergic blocking effects of sotalol in anesthetized dogs. J Am Coll Cardiol 13 (1989) 1190-1194
86. Woosley R.L., Barbey J.T., Wang T., and Funck-Brentano C. Concentration/response relations for the multiple antiarrhythmic actions of sotalol. Am J Cardiol 65 (1990) 22A-27A discussion 35A-36A
87. Antonaccio M.J., and Gomoll A. Pharmacologic basis of the antiarrhythmic and hemodynamic effects of sotalol. Am J Cardiol 72 (1993) 27A-37A
88. Nielsen B.L., and Jorgensen F.S. Propranolol (Inderal) in cardiac arrhythmias. Acta Med Scand 180 (1966) 631-638